AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Uniglip M 2mg/500mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Unimarck Healthcare Ltd

Salt Composition

Glimepiride (2mg) + Metformin (500mg)

Overview Uniglip M 2mg/500mg Tablet ER

GlucoDuo 2mg/500mg Extended-Release tablets are classified as antidiabetic medications. This dual-action formulation manages type 2 diabetes in adults by regulating blood glucose. Administer GlucoDuo with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your glycemic response. Continuous use is crucial; abrupt cessation, without physician consultation, risks elevated blood sugar, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medication complements a comprehensive diabetes management plan encompassing a balanced diet, regular physical activity, and weight management as recommended by your doctor. Lifestyle choices significantly impact diabetes control. Hypoglycemia (low blood sugar) is the most frequent adverse effect. Familiarize yourself with its symptoms—sweating, lightheadedness, headache, tremors—and appropriate countermeasures. Maintain regular mealtimes and carry a rapid-acting glucose source (e.g., sweets, juice). Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemia. Other possible side effects include altered taste perception, nausea, diarrhea, abdominal discomfort, headache, and upper respiratory infections. Weight gain may occur in some individuals. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Disclose any history of heart disease to your physician prior to commencing treatment. Pregnant or lactating individuals should seek medical advice before use. Regular blood glucose monitoring is essential, and your doctor may order blood tests to assess blood cell counts and liver function.

Primary Ingredients of Uniglip M 2mg/500mg Tablet ER

No text was provided to rewrite. Please provide the text you wish to have rephrased.

Uses of Uniglip M 2mg/500mg Tablet ER

Managing type 2 diabetes

Major Benefits of Uniglip M 2mg/500mg Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Uniglip M 2mg/500mg Extended-Release tablet whole; avoid chewing, crushing, or breaking it. Administer this medication with a meal.

Common Side effects of Uniglip M 2mg/500mg Tablet ER:

  • Headache
  • Hypoglycemia (low blood glucose level)
  • Nausea
  • Diarrhea

How to use Uniglip M 2mg/500mg Tablet ER:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Uniglip M 2mg/500mg Extended-Release Tablet with food.

How Uniglip M 2mg/500mg Tablet ER works:

Uniglip M 2mg/500mg Extended-Release tablets contain glimepiride and metformin, two medications that manage blood sugar. Glimepiride, a sulfonylurea, stimulates the pancreas to release more insulin, thus reducing blood glucose levels. Metformin, a biguanide, acts by decreasing liver glucose production, slowing intestinal glucose absorption, and enhancing insulin sensitivity.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol while taking Uniglip M 2mg/500mg Tablet ER is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Uniglip M 2mg/500mg tablets might pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the potential advantages against the risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingUNSAFE

Extended-release Uniglip M 2mg/500mg tablets are contraindicated for breastfeeding mothers. Evidence indicates potential infant toxicity from this medication.

DrivingDrivingCAUTION

Driving may be impaired by excessively low or high blood glucose levels. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Uniglip M 2mg/500mg Extended-Release tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates the use of Uniglip M 2mg/500mg Extended-Release tablets. Physician consultation is essential. Regular kidney function monitoring is recommended during treatment.

LiverLiverCAUTION

Patients with liver impairment should use Uniglip M 2mg/500mg Extended-Release tablets cautiously. Dosage modification may be necessary. Consult your physician. A low initial dose of Uniglip M 2mg/500mg Extended-Release tablets is typically prescribed for those with mild to moderate liver disease; however, its use is contraindicated in patients with severe hepatic dysfunction.

What if you forget to take Uniglip M 2mg/500mg Tablet ER :

Should you forget a Uniglip M 2mg/500mg Extended-Release Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Uniglip M 2mg/500mg Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Uniglip M 2mg/500mg Tablet ER

Store this medication in its original, tightly closed container, as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Uniglip M 2mg/500mg Tablet ER can cause lactic acidosis (MALA, or Metformin-associated lactic acidosis), a serious medical emergency resulting from excessive blood lactic acid. This rare but harmful side effect is more likely in patients with kidney disease, older adults, or those who consume large amounts of alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If you experience these, discontinue Uniglip M 2mg/500mg Tablet ER and seek immediate medical attention.
Uniglip M 2mg/500mg Extended-Release tablets combine glimepiride and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Glimepiride stimulates insulin release from the pancreas, while metformin reduces liver glucose production and enhances insulin sensitivity. It's not suitable for type 1 diabetes.
Uniglip M 2mg/500mg Tablet ER may cause common side effects such as hypoglycemia, altered taste, nausea, stomach pain, diarrhea, and headache. Rare but serious side effects include lactic acidosis. Prolonged use can also result in vitamin B12 deficiency.
Prolonged use of Uniglip M 2mg/500mg Tablet ER can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency, if left untreated, may result in anemia, neurological issues such as tingling, numbness in the extremities, weakness, urinary problems, cognitive changes, and ataxia. To mitigate this risk, supplemental vitamin B12 is recommended at least annually by some researchers.
Uniglip M 2mg/500mg ER tablets can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Regular blood sugar monitoring is crucial. Carry a fast-acting sugar source, such as glucose tablets, honey, or fruit juice, at all times.
Combining Uniglip M 2mg/500mg Tablet ER with alcohol is unsafe. This combination may cause dangerously low blood sugar (hypoglycemia) and raise your risk of lactic acidosis.
Uniglip M 2mg/500mg Table...
130
MRP 150
13% off